| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Eculizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Hemoglobinuria, Paroxysmal | Details | |
| Eculizumab biosimilar (IBC GENERIUM) | Phase 3 Clinical | Ibc Generium | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Details | |
| Eculizumab biosimilar (Biocad) | BCD-148 | Phase 3 Clinical | BIOCAD JSC | Hemoglobinuria, Paroxysmal | Details |
| Cemdisiran | ALN-CC5; AD-62643; ALN-62643; L96 | Phase 3 Clinical | Alnylam Pharmaceuticals Inc | Atypical Hemolytic Uremic Syndrome; Geographic Atrophy; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Macular Degeneration; Myasthenia Gravis; Myositis; Myositis, Inclusion Body | Details |
| Tesidolumab | NOV-4; LFG-316 | Phase 2 Clinical | Morphosys Ag, Novartis Pharma Ag | Geographic Atrophy; Hemoglobinuria, Paroxysmal; Macular Degeneration; Panuveitis; Rejection of renal transplantation; Uveitis, Intermediate; Uveitis, Posterior; Wet Macular Degeneration | Details |
| IM-101 | IM-101 | Phase 2 Clinical | ImmunAbs Inc | Autoimmune Diseases; Myasthenia Gravis | Details |
| ABBV-6628 | ABBV-6628 | Phase 2 Clinical | Abbvie Inc | Geographic Atrophy; Macular Degeneration | Details |
| OCUL-101 | OCUL101 | Phase 2 Clinical | Shenzhen Oukejian Biomedical Technology Co Ltd | Diabetic macular oedema; Geographic Atrophy; Macular Degeneration; Retinal Neovascularization | Details |
| KRIYA-825 | KRIYA-825; VV-14295 | Phase 2 Clinical | Kriya Therapeutics Inc | Geographic Atrophy | Details |
| LP-005 | LP-005; RX-001 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies | Details |
| Vensobafusp alfa | P014; KP-104 | Phase 2 Clinical | Kira Pharmaceuticals LLC | Glomerulonephritis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Erythematosus, Systemic; Thrombotic Microangiopathies | Details |
| Omoprubart | CAN-106 | Phase 2 Clinical | Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd | Genetic Diseases, Inborn; Hemoglobinuria, Paroxysmal | Details |
| ALXN-5500 | ALXN-5500 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
| RLYB-116 | RLYB-116 | Phase 1 Clinical | Affibody Ab, Swedish Orphan Biovitrum (Sobi) | Autoimmune Diseases; Hematologic Diseases; Immune System Diseases; Inflammation | Details |
| SYH-2061 | SYH2061; SYH-2061 | Phase 1 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Complement-Mediated Diseases; Glomerulonephritis, IGA; Nephrosis | Details |
| NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
| Eculizumab biosimilar (Turgut Ardika) | TUR03; TUR-03 | Phase 1 Clinical | Turgut Ardika Pty Ltd | Details | |
| EA-5 | EA-5; EA5 | Phase 1 Clinical | Shandong Lanyi Pharmaceutical Technology Co Ltd | Antiphospholipid Syndrome; Hemoglobinuria, Paroxysmal; Kidney Diseases; Myasthenia Gravis; Thrombotic Microangiopathies | Details |
| RBD-7007 | RBD-7007 | Phase 1 Clinical | Suzhou Ribo Life Science Co Ltd | Glomerulonephritis, IGA | Details |
| eculizumab biosimilar(Isu Abxis) | ISU-305 | Phase 1 Clinical | Isu Abxis Co Ltd | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Avacincaptad pegol sodium | ARC-1905; ARC-187 | Approved | Archemix Corp | Zimura, Izervay | United States | Macular Degeneration; Geographic Atrophy | Iveric Bio Inc, Astellas Pharma Inc | 2023-08-04 | Geographic Atrophy; Macular Degeneration; Polypoidal choroidal vasculopathy | Details |
| Zilucoplan Sodium | RA-101495-SC; RA-101495; ZLP-AI | Approved | Ra Pharmaceuticals Inc, Ucb Sa | ZILBRYSQ, Zilbrysq, 卓倍可 | Japan | Myasthenia Gravis | Ucb Japan Co Ltd | 2023-09-25 | Amyotrophic Lateral Sclerosis; Coronavirus Disease 2019 (COVID-19); Hemoglobinuria, Paroxysmal; Muscular Diseases; Myasthenia Gravis | Details |
| Crovalimab | RO-7112689/F01; SKY-59; RO711269; RO-711269; RG-6107; CH-7092230; RO-7092230; RO-7112689 | Approved | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | 派圣凯, Piasky | Mainland China | Hemoglobinuria, Paroxysmal | Roche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc | 2024-02-06 | Anemia, Sickle Cell; Antiphospholipid Syndrome; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Hemoglobinuria, Paroxysmal | Details |
| Ravulizumab | ALXN-1810; ALXN-1210 | Approved | Alexion Pharmaceuticals Inc, Xencor Inc | Ultomiris, 伟立瑞 | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2018-12-21 | Acute Kidney Injury; Acute Lung Injury; Amyotrophic Lateral Sclerosis; Atypical Hemolytic Uremic Syndrome; Coronavirus Disease 2019 (COVID-19); Delayed Graft Function; Dermatomyositis; Glomerulonephritis, IGA; Heart Diseases; Hemoglobinuria, Paroxysmal; Immunoglobulin A Vasculitis Associated Nephritis; Kidney Diseases; Kidney Failure, Chronic; Lupus Nephritis; Myasthenia Gravis; Neuromyelitis Optica; Pneumonia, Viral; Purpura, Schoenlein-Henoch; Rejection of renal transplantation; Renal Insufficiency, Chronic; Respiratory Distress Syndrome, Adult; Thrombotic Microangiopathies | Details |
| Eculizumab | LEX-98; h-5G1.1; 5G1-1; HAL-1 | Approved | Alexion Pharmaceuticals Inc | Soliris, 舒立瑞 | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2007-03-16 | Anemia, Hemolytic, Autoimmune; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Asthma; Atypical Hemolytic Uremic Syndrome; Delayed Graft Function; Diabetes Mellitus; End Stage Liver Disease; Glomerulonephritis, Membranoproliferative; Guillain-Barre Syndrome; HELLP Syndrome; Hemoglobinuria, Paroxysmal; Infant, Newborn, Diseases; Kidney Failure, Chronic; Macular Degeneration; Myasthenia Gravis; Nasopharyngeal Carcinoma; Neuromyelitis Optica; Parturition; Pre-Eclampsia; Rejection of renal transplantation; Rejection of organ transplantation; Thrombocytopenia; Urea Cycle Disorders, Inborn; Vagus Nerve Diseases | Details |
| Pozelimab | REGN-3918 | Approved | Regeneron Pharmaceuticals Inc | VEOPOZ | United States | Protein-Losing Enteropathies | Regeneron Pharmaceuticals Inc | 2023-08-18 | Geographic Atrophy; Hemoglobinuria, Paroxysmal; Myasthenia Gravis; Protein-Losing Enteropathies | Details |
| Eculizumab biosimilar (Amgen) | ABP-959 | Approved | Amgen Inc | BKEMV | United States | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Amgen Inc | 2024-05-28 | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Details |
| Eculizumab biosimilar (Samsung Bioepis) | SB-12; AM004; AMT-904; SB12 | Approved | Samsung Bioepis Co Ltd | Epysqli, EPYSQLI | EU | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Samsung Bioepis Nl Bv | 2023-05-26 | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Details |
